7-nitroindazole has been researched along with Parkinson Disease in 13 studies
7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with mangiferin and 7-NI significantly increases locomotor parameters in 6-OHDA lesioned rats." | 1.72 | Effects of mangiferin and its combination with nNOS inhibitor 7-nitro-indazole (7-NI) in 6-hydroxydopamine (6-OHDA) lesioned Parkinson's disease rats. ( Chaudhary, MJ; Nath, R; Pal, R; Tiwari, PC, 2022) |
| "Chronic L-DOPA pharmacotherapy in Parkinson's disease is often accompanied by the development of abnormal and excessive movements known as L-DOPA-induced dyskinesia." | 1.35 | Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. ( Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V, 2009) |
| "The neuropathological hallmark of Parkinson's disease (PD) is the selective degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc)." | 1.33 | 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. ( Benigno, A; Crescimanno, G; Di Giovanni, G; Di Matteo, V; Esposito, E; Giuliano, DA; Pierucci, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Tiwari, PC | 1 |
| Chaudhary, MJ | 1 |
| Pal, R | 1 |
| Nath, R | 1 |
| Herrero, MT | 1 |
| Yuste, JE | 1 |
| Cuenca-Bermejo, L | 1 |
| Almela, P | 1 |
| Arenas-Betancur, L | 1 |
| De Pablos, V | 1 |
| Gonzalez-Cuello, A | 1 |
| Del Bel, E | 1 |
| Navarro-Zaragoza, J | 1 |
| Fernández-Villalba, E | 1 |
| Solís, O | 1 |
| Espadas, I | 1 |
| Del-Bel, EA | 2 |
| Moratalla, R | 1 |
| Bortolanza, M | 2 |
| Cavalcanti-Kiwiatkoski, R | 1 |
| Padovan-Neto, FE | 2 |
| da-Silva, CA | 2 |
| Mitkovski, M | 1 |
| Raisman-Vozari, R | 1 |
| Del-Bel, E | 2 |
| Kumari, R | 1 |
| Kumar, JB | 1 |
| Luthra, PM | 1 |
| Bariotto-Dos-Santos, KD | 1 |
| Dos-Santos-Pereira, M | 1 |
| Di Matteo, V | 2 |
| Pierucci, M | 2 |
| Benigno, A | 2 |
| Crescimanno, G | 2 |
| Esposito, E | 2 |
| Di Giovanni, G | 2 |
| Echeverry, MB | 1 |
| Tumas, V | 1 |
| Giuliano, DA | 1 |
| Rajakumar, B | 1 |
| Flumerfelt, BA | 1 |
| Hrycyshyn, AW | 1 |
| Rajakumar, N | 1 |
| Haik, KL | 1 |
| Shear, DA | 1 |
| Hargrove, C | 1 |
| Patton, J | 1 |
| Mazei-Robison, M | 1 |
| Sandstrom, MI | 1 |
| Dunbar, GL | 1 |
| Przedborski, S | 1 |
| Jackson-Lewis, V | 1 |
| Yokoyama, R | 1 |
| Shibata, T | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Snyder, SH | 1 |
13 other studies available for 7-nitroindazole and Parkinson Disease
| Article | Year |
|---|---|
Effects of mangiferin and its combination with nNOS inhibitor 7-nitro-indazole (7-NI) in 6-hydroxydopamine (6-OHDA) lesioned Parkinson's disease rats.
Topics: Animals; Male; Nitrites; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2022 |
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian D | 2023 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dop | 2015 |
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflamma | 2015 |
Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Topics: Animals; Brain; Catalase; Dopamine; Female; Glutathione; Indazoles; Lipid Peroxidation; Motor Skills | 2015 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, | 2016 |
Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study .
Topics: Animals; Corpus Striatum; Indazoles; Male; Molsidomine; Nitric Oxide; Nitric Oxide Donors; Oxidopami | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; En | 2009 |
7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Indazoles | 2006 |
Nitric oxide-containing neurons in long-term grafts in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Choline; Disease Models, Animal; Female; In | 2007 |
7-nitroindazole attenuates 6-hydroxydopamine-induced spatial learning deficits and dopamine neuron loss in a presymptomatic animal model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Indazoles; Learni | 2008 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz | 1996 |
No NO prevents parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Enzyme Inhi | 1996 |